VOY-101 / Perceive Bio - LARVOL DELTA

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=60 | Active, not recruiting | Sponsor: Perceive Biotherapeutics, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2028 ➔ Jun 2028 | Trial primary completion date: Jun 2027 ➔ Oct 2027

Enrollment closed • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

OASIS: Long-Term Follow Up of VOY-101 Non-nAMD Extension Study (clinicaltrials.gov) - P=N/A | N=88 | Enrolling by invitation | Sponsor: Perceive Biotherapeutics, Inc.

New trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase 1 Results of VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy (ARVO 2026) - "To date, VOY-101 has been safe and well tolerated in the 24 Phase 1 subjects and 8-9 fold increases of the drug have been detected in the eye providing evidence that the gene therapy is working. These data support enrolling patients in Phase 2 for further study to build information on its safety and efficacy."

First-in-human • Gene therapy • P1 data • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Perceive Biotherapeutics, Inc. | N=140 ➔ 60 | Trial completion date: Oct 2027 ➔ Mar 2028 | Trial primary completion date: Oct 2026 ➔ Jun 2027

Enrollment change • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=140 | Recruiting | Sponsor: Perceive Biotherapeutics, Inc. | N=66 ➔ 140

Enrollment change • Metastases • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=45 | Active, not recruiting | Sponsor: Perceive Biotherapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

VOY-101 in Advanced Non-Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=66 | Recruiting | Sponsor: Perceive Biotherapeutics, Inc.

Metastases • New P1/2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=45 | Recruiting | Sponsor: Perceive Biotherapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=45 | Not yet recruiting | Sponsor: Perceive Biotherapeutics, Inc. | Trial completion date: Jul 2026 ➔ Oct 2025 | Initiation date: Jul 2022 ➔ Oct 2022 | Trial primary completion date: Jul 2026 ➔ Oct 2025

Trial completion date • Trial initiation date • Trial primary completion date • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=35 | Not yet recruiting | Sponsor: Perceive Biotherapeutics, Inc.

New P1/2 trial • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders